The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 03, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Promoter Ravi Agrawal, trustee of Ravi Agrawal Trust (holding 1,62,42,904 shares or 13.00% of Ajanta Pharma), has disclosed creation of pledge on 11,52,777 equity shares and release of pledge on 46,499 shares. The reason for creation is 'Re-Financing' and for release is 'Excess Pledge'. Lenders involved include Emerging India Credit Opportunities Fund, Aditya Birla Capital, Infina Finance, Deutsche Bank, HSBC Direct, and Bajaj Finance. Post-event, the total encumbered shares stand at 71,13,920 (5.69% of share capital), up from around 59,64,476 (4.77%) earlier. Multiple pledge creation and release events were executed on September 29 and September 30, 2025 across various lenders, suggesting a re-financing exercise to consolidate debt obligations.
Net pledged shares rose modestly to 5.69% of capital from ~4.77%, reflecting routine re-financing rather than distress. This is a normal treasury management activity and not a material negative signal for shareholders; existing investors should note the marginally higher encumbrance but the absolute level remains low.